REG - AstraZeneca PLC - AZ completes US licensing agreement with Ironwood <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

03/06/2016 07:00

RNS Number : 1004A
AstraZeneca PLC
03 June 2016
ASTRAZENECA COMPLETES US LICENSING AGREEMENT WITH IRONWOOD PHARMACEUTICALS FOR LESINURAD
AstraZeneca today announced that it has completed the licensing agreement with Ironwood Pharmaceuticals for the exclusive US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol. Zurampic is approved in the US, in combination with a xanthine oxidase inhibitor, for the treatment of hyperuricemia associated with uncontrolled gout. The fixed-dose combination will be submitted for regulatory review in the second half of 2016.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
Media Enquiries

Neil Burrows
UK/Global
+44 7824 350541
Vanessa Rhodes
UK/Global
+44 7880 400690
Karen Birmingham
UK/Global
+44 7818 524012
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677
Investor Enquiries


UK


Thomas Kudsk Larsen

+44 7818 524185
Nick Stone
RIA
+44 7717 618834
Henry Wheeler
Oncology
+44 7788 354619
Craig Marks
Finance
+44 7881 615764
Christer Gruvris
ING
+44 7827 836825
US


Lindsey Trickett
 CVMD
+1 240 543 7970
Mitchell Chan
 Oncology
+1 240 477 3771
Dial / Toll-Free

+1 866 381 7277
Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease, ING - Infection, Neuroscience and Gastrointestinal
3 June 2016
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
AGRLLFETRVIFIIR